ARRDC4 Antibody

What is ARRDC4 and what cellular functions does it regulate?

ARRDC4 belongs to the alpha-arrestin family of proteins that function as adaptor proteins with conserved roles in regulating nutrient transporter trafficking and cellular metabolism. ARRDC4 is localized in multiple cellular compartments including the cytoplasm, plasma membrane, endosomes, and extracellular vesicles. It plays critical roles in glucose metabolism by binding to glucose transporters (particularly GLUT1), inducing their endocytosis, and blocking cellular glucose uptake in cardiomyocytes. Unlike its homologue TXNIP, ARRDC4 operates through distinct molecular pathways, particularly mediating cardiomyocyte death through glucose deprivation and endoplasmic reticulum (ER) stress rather than oxidative stress .

What are the optimal methods for detecting ARRDC4 in cellular samples?

For detecting ARRDC4 in human samples, Western blot represents the primary validated application, using a dilution range of 1:500-1:2000 for optimal results. When performing Western blots, researchers should expect to observe ARRDC4 at approximately 45kDa, which matches its calculated molecular weight. For cellular localization studies, immunostaining protocols should be optimized to detect ARRDC4 in multiple compartments including cytoplasm, early endosomes, general endosomes, extracellular vesicles, and plasma membrane. ELISA may also be used as a complementary detection method for quantitative analysis of ARRDC4 expression levels .

How should researchers validate ARRDC4 antibody specificity for their experimental systems?

To validate antibody specificity, researchers should:

• Include appropriate positive controls (e.g., PC-3 cells which express ARRDC4)

• Use knockout or knockdown models as negative controls (the Arrdc4-KO mouse model created by CRISPR/Cas9 genome editing with deletion of exons 1-8 provides an excellent negative control system)

• Confirm target protein size (45kDa) via Western blot

• Perform peptide competition assays using the immunogen peptide (corresponding to a sequence within amino acids 300-400 of human ARRDC4)

• Verify results with alternative ARRDC4 antibodies targeting different epitopes

What are the best protocols for studying ARRDC4-GLUT1 interactions in cardiomyocytes?

For studying ARRDC4-GLUT1 interactions in cardiomyocytes, researchers should implement a multi-faceted approach:

• Co-immunoprecipitation assays using ARRDC4 antibodies to pull down protein complexes, followed by immunoblotting for GLUT1

• Proximity ligation assays to visualize protein-protein interactions in situ

• Fluorescence microscopy using tagged proteins (e.g., GLUT1-mCherry and ARRDC4-GFP) to track co-localization in real-time

• Surface expression quantification using epitope-tagged GLUT1 constructs (such as HA-GLUT1) with non-permeabilized immunostaining to assess GLUT1 internalization

• Clathrin and AP-2 co-localization studies to confirm the endocytic pathway

Researchers should analyze these interactions under both normoxic and hypoxic conditions, as hypoxia affects GLUT1 surface expression and ARRDC4 activity .

How can researchers effectively assess ARRDC4's impact on glucose uptake and metabolism?

To assess ARRDC4's impact on glucose uptake and metabolism, implement the following methodological approaches:

• Glucose uptake assays: Use radiolabeled glucose (2-DG) to measure uptake rates in cells with manipulated ARRDC4 expression

• Surface GLUT1 quantification: Employ flow cytometry with HA-tagged GLUT1 and fluorophore-conjugated antibodies to measure plasma membrane expression

• Metabolic profiling: Use Seahorse analyzers to measure glycolytic flux and mitochondrial respiration in ARRDC4-overexpressing or knockout models

• Glycogen storage assessment: Perform periodic acid-Schiff (PAS) staining to measure glycogen content in cardiac tissues

• In vivo glucose metabolism: Use positron emission tomography (PET) with 18F-FDG to quantify myocardial glucose uptake in animal models

Comparing wild-type and Arrdc4-knockout mouse models under both normal and stress conditions (e.g., ischemia, diabetes) provides valuable insights into ARRDC4's metabolic regulatory functions .

How does ARRDC4 contribute to cardiac pathophysiology during ischemia?

ARRDC4 contributes to cardiac pathophysiology during ischemia through several interconnected mechanisms:

• Glucose transport inhibition: ARRDC4 binds to GLUT1 and induces its endocytosis, reducing glucose uptake capacity during ischemia when glucose becomes the preferred energy substrate

• ER stress induction: ARRDC4 uniquely mediates cardiomyocyte death through glucose deprivation-induced ER stress, as evidenced by:

  • Increased XBP1 splicing (a marker of ER stress)

  • Enhanced sensitivity to tunicamycin-induced unfolded protein response

  • Activation of the ER stress pathway

• Energy depletion: ARRDC4 overexpression depletes intracellular ATP, predisposing cells to both apoptotic and necrotic death pathways

• Cell death promotion: ARRDC4 induces cardiomyocyte cytotoxicity as demonstrated by:

  • Increased LDH release

  • Cellular trypan blue uptake

  • Activation of caspase-3/7

  • Increased Annexin V-positive apoptosis

  • DNA Nuclear Green DCS1-positive necrosis

Deletion of Arrdc4 has been shown to improve energy homeostasis during ischemia and protect cardiomyocytes against myocardial infarction, highlighting its central role in ischemic injury pathways .

What experimental models best demonstrate ARRDC4's role in diabetic cardiac dysfunction?

The optimal experimental models for investigating ARRDC4's role in diabetic cardiac dysfunction include:

• In vitro models:

  • Primary cardiomyocytes cultured in high glucose conditions

  • Human muscular cells from type 2 diabetic patients

• In vivo models:

  • Insulin-deficient diabetic mice (comparing wild-type vs. Arrdc4-KO)

  • Multiple types of mouse models of diabetes with prolonged hyperglycemia

• Functional assessments:

  • Stress hemodynamic analysis to evaluate cardiac inotropic/chronotropic reserve

  • Treadmill exhaustion testing for exercise endurance evaluation

  • Advanced glycation end-products quantification

  • Oxidative and ER stress marker measurements

• Tissue-specific models:

  • Cardiac-specific ARRDC4 overexpression using adeno-associated virus

These models have demonstrated that Arrdc4-knockout mice exhibit greater cardiac inotropic/chronotropic reserve with higher exercise endurance than wild-type animals under diabetes conditions, providing important insights into ARRDC4's role in diabetic cardiac dysfunction .

How does ARRDC4 regulate innate immune responses during viral infection?

ARRDC4 plays a significant role in regulating innate immune responses during viral infection, particularly during Enterovirus 71 (EV71) infection, through the following mechanisms:

• MDA5 interaction and activation:

  • ARRDC4 interacts with MDA5 (a viral RNA sensor) via its arrestin-like N domain

  • This interaction recruits TRIM65 to enhance K63 ubiquitination of MDA5

  • Enhanced ubiquitination activates the downstream innate signaling pathway

• Proinflammatory cytokine regulation:

  • ARRDC4 expression levels positively correlate with serum concentrations of inflammatory cytokines (IL-6, TNF-α, and CCL3) in clinical specimens

  • ARRDC4 contributes to the transcriptional activation of proinflammatory cytokines during EV71 infection

• Expression induction:

  • EV71 infection increases ARRDC4 expression in THP-1-derived macrophages

  • This has been verified in both EV71-infected HFMD patients and healthy controls

These findings highlight ARRDC4's previously uncharacterized function in innate immunity, particularly its role in regulating MDA5 activation following viral infection .

What techniques are most effective for studying ARRDC4's interactions with immune signaling components?

To effectively study ARRDC4's interactions with immune signaling components, researchers should employ the following techniques:

• Protein-protein interaction analyses:

  • Co-immunoprecipitation assays using ARRDC4 antibodies to identify binding partners

  • Proximity ligation assays for in situ visualization of interactions

  • Domain mapping through truncation mutants to identify specific interaction interfaces

  • Yeast two-hybrid screening for novel interaction partners

• Ubiquitination studies:

  • In vitro ubiquitination assays with purified components

  • Ubiquitin pulldown assays to detect specific ubiquitin linkages (K63 vs. K48)

  • Immunoblotting for ubiquitinated species after MDA5 immunoprecipitation

• Signaling pathway activation assessment:

  • Luciferase reporter assays for transcription factor activation

  • Phosphorylation status of downstream signaling molecules

  • RT-qPCR analysis of cytokine gene expression

  • ELISA measurement of secreted cytokines

• Functional immune response evaluation:

  • Viral replication assays in cells with manipulated ARRDC4 expression

  • Cytokine profiling in patient samples correlated with ARRDC4 expression levels

  • Immune cell activation analyses following ARRDC4 modulation

These methodologies allow comprehensive investigation of ARRDC4's role in immune signaling networks and its potential as a therapeutic target for modulating inflammatory responses .

How can structure-function analyses of ARRDC4 guide therapeutic development for cardiac ischemia?

Structure-function analyses of ARRDC4 can guide therapeutic development for cardiac ischemia through several sophisticated approaches:

• Mapping of critical interaction domains:

  • Scanning mutagenesis to identify specific residues in the C-terminal arrestin-fold domain that form the GLUT1 interaction interface

  • Deep-learning Artificial Intelligence approaches to predict and validate protein-protein interaction sites

  • Targeted disruption of these interaction interfaces using small molecules or peptides

• Development of domain-specific inhibitors:

  • Design of competitive peptides that mimic the GLUT1-binding region of ARRDC4

  • Small molecule screening for compounds that disrupt ARRDC4-GLUT1 interaction

  • Structure-based drug design targeting the C-terminal arrestin-fold domain

• Validation in disease models:

  • Testing candidate inhibitors in myocardial infarction mouse models

  • Evaluating effects on glucose uptake, glycogen storage, and ER stress markers

  • Assessing cardioprotective effects through functional cardiac measurements

• Therapeutic target specificity:

  • Comparative analysis with TXNIP inhibition to ensure unique targeting

  • Assessment of effects on normal glucose homeostasis

  • Evaluation of potential off-target effects in other tissues

These approaches leveraging structure-function relationships of ARRDC4 could lead to novel therapeutic strategies for protecting cardiomyocytes against ischemic injury by preserving glucose uptake capacity and preventing ER stress-induced cell death .

What are the most sensitive methods for detecting tissue-specific changes in ARRDC4 expression under pathological conditions?

For detecting tissue-specific changes in ARRDC4 expression under pathological conditions, researchers should implement these sensitive methodologies:

• Transcriptional analysis:

  • RNA-seq for comprehensive transcriptome profiling

  • Single-cell RNA-seq to identify cell-type specific expression changes

  • Quantitative RT-PCR with highly specific primers targeting exons 1-8

  • In situ hybridization for spatial expression analysis in tissue sections

• Protein detection and quantification:

  • Multiplexed immunohistochemistry with digital image analysis

  • Laser capture microdissection combined with Western blotting or mass spectrometry

  • Proximity extension assays for ultrasensitive protein quantification

  • FACS-based intracellular staining for cell-type specific expression

• Translational regulation:

  • Polysome profiling to assess translation efficiency

  • Ribosome footprinting to analyze active translation of ARRDC4 mRNA

• Regulatory mechanisms:

  • ChIP-seq for identifying MondoA binding to the ARRDC4 promoter under high glucose conditions

  • Analysis of nuclear translocation of transcription factors that regulate ARRDC4

  • Epigenetic profiling to identify regulatory modifications affecting ARRDC4 expression

These methodologies provide comprehensive insights into the tissue-specific regulation of ARRDC4 expression under various pathological conditions, including diabetes, ischemia, and viral infections .

How can ARRDC4 knockout models be effectively utilized to study metabolic adaptations across multiple organ systems?

ARRDC4 knockout models can be effectively utilized to study metabolic adaptations across multiple organ systems through the following comprehensive approach:

• Tissue-specific metabolic profiling:

  • Comparative metabolomics of heart, skeletal muscle, liver, and adipose tissue

  • Mitochondrial respiration analysis in isolated tissue samples

  • Glycolytic flux measurement using stable isotope tracing

  • Glycogen content quantification across different tissues

• Systemic metabolic phenotyping:

  • Glucose and insulin tolerance testing

  • Hyperinsulinemic-euglycemic clamp studies

  • Continuous glucose monitoring during rest and exercise

  • Metabolic cage studies to assess whole-body energy expenditure

• Stress response evaluation:

  • Ischemia-reperfusion protocols in multiple organs

  • Exercise capacity testing with tissue sampling

  • Diabetic models with hyperglycemic stress

  • Fasting-refeeding cycles to assess metabolic flexibility

• Cross-talk between organ systems:

  • Analysis of circulating metabolites and signaling molecules

  • Tissue-specific conditional knockout models to dissect organ-specific contributions

  • Ex vivo perfusion studies to isolate organ-specific metabolic adaptations

  • Transplantation studies to distinguish cell-autonomous from systemic effects

These approaches leverage the Arrdc4-knockout mouse model to comprehensively map metabolic adaptations across organ systems, with particular attention to the interconnected responses of cardiac and skeletal muscle tissues during metabolic stress conditions .

What are the most common technical challenges when using ARRDC4 antibodies and how can they be overcome?

Common technical challenges when using ARRDC4 antibodies include:

• Specificity issues:

  • Challenge: Cross-reactivity with other alpha-arrestin family members (especially TXNIP)

  • Solution: Validate antibody specificity using Arrdc4-knockout tissues/cells as negative controls; use antibodies targeting unique epitopes (e.g., within amino acids 300-400 of human ARRDC4)

• Detection sensitivity:

  • Challenge: Low endogenous expression levels in some cell types

  • Solution: Optimize antibody concentration (1:500-1:2000 for Western blot); use signal amplification methods; implement immunoprecipitation before detection

• Subcellular localization detection:

  • Challenge: ARRDC4 distributes across multiple cellular compartments

  • Solution: Use co-localization markers for specific compartments (plasma membrane, endosomes, etc.); employ super-resolution microscopy techniques; use fractionation approaches

• Antibody performance variability:

  • Challenge: Lot-to-lot variation in commercial antibodies

  • Solution: Validate each new lot against previous standards; maintain positive control samples (e.g., PC-3 cells); use recombinant ARRDC4 as a standard

• Species cross-reactivity:

  • Challenge: Limited cross-reactivity across experimental models

  • Solution: Verify antibody epitope conservation across species; select antibodies validated for your specific experimental model; consider developing custom antibodies for specialized applications

By implementing these solutions, researchers can overcome common technical challenges and obtain reliable results when using ARRDC4 antibodies for various experimental applications .

How should researchers design experiments to differentiate between ARRDC4 and TXNIP functions despite their structural similarities?

To effectively differentiate between ARRDC4 and TXNIP functions despite their structural similarities, researchers should implement the following experimental design strategies:

• Comparative knockout/knockdown studies:

  • Generate single and double knockouts/knockdowns of ARRDC4 and TXNIP

  • Assess phenotypic differences and potential compensatory mechanisms

  • Compare tissue-specific expression patterns and subcellular localization

• Molecular pathway analysis:

  • Evaluate oxidative stress markers (specific to TXNIP function)

  • Measure ER stress indicators (more associated with ARRDC4 function)

  • Assess glucose deprivation effects separately from redox status

• Domain-swapping experiments:

  • Create chimeric proteins with domains exchanged between ARRDC4 and TXNIP

  • Determine which domains confer specific functional properties

  • Map interaction interfaces with shared binding partners

• Differential binding partner identification:

  • Perform comparative immunoprecipitation-mass spectrometry

  • Validate unique interaction partners for each protein

  • Map interaction networks to distinct cellular pathways

• Tissue-specific and condition-specific expression analysis:

  • Compare expression patterns across tissues and under various stress conditions

  • Identify differential regulatory mechanisms controlling expression

  • Analyze promoter regions and transcription factor binding sites

These experimental approaches allow researchers to delineate the unique functions of ARRDC4 and TXNIP despite their structural similarities, revealing their distinct roles in metabolism, stress responses, and disease pathogenesis .